
Lymphedema - Pipeline Insight, 2025
Description
DelveInsight’s, “Lymphedema – Pipeline Insight, 2025,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Lymphedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lymphedema: Overview
Lymphedema is the condition that may be caused in the body due to cancer and as a side effect of the cancer treatment. It occurs due to the buildup fluids in soft body tissues which lead to swelling in the organs, particularly limbs. Lymphedema can lead to psychological, physical, and social problems in patients. Symptoms
Symptoms of lymphedema include loss of hair, troubled sleep, a burning sensation in legs, itching in toes and legs, a feeling of tightness when clothes, bracelets, shoes, etc. are worn, skin thickening without any changes in the skin, trouble moving arms or legs, heaviness in arms or legs, and swelling in arms or legs, which may include toes and fingers.
Diagnosis
Diagnosis may be based on past cancer history of the patient. Test such as Doppler ultrasound, CT scan, MRI scan, and radionuclide imaging of lymphatic system (lymphoscintigraphy) may be carried out.
Treatment
At present, there is no cure for lymphedema. The treatment is symptomatic and major focus is on controlling the pain and swelling. The treatment regimen may include massages, exercises, pneumatic compression, compression garments, and bandaging of the affected area.
Lymphedema Emerging Drugs Chapters
This segment of the Lymphedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, and phase I/II. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lymphedema Emerging Drugs
Lymfactin: Herantis Pharma
Lymfactin is a product which is being developed by Herantis Pharma. It is derived from the Vascular Endothelial Growth Factor C (VEGF-C), a natural human protein, which is crucial for the growth of new lymphatic vessels. Lymphfactin is a gene therapy product which works by the delivery of the human gene coding for VEGF-C, which in turn initiates the new lymphatic vessel formation. It is administered locally at the required site. It is currently available for licensing.
LYT-100:PureTechHealth
PureTech Health acquired LYT-100 in July 2019 from Auspex Pharmaceuticals. The drug candidate is in the phase I/II of drug development. The company believes that LYT-100 holds the potential to be evaluated for various inflammatory and fibrotic conditions besides being developed for lymphedema.
Further product details are provided in the report……..
Lymphedema: Therapeutic Assessment
This segment of the report provides insights about the different Lymphedema drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
Lymphedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphedema drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Lymphedema: Overview
Lymphedema is the condition that may be caused in the body due to cancer and as a side effect of the cancer treatment. It occurs due to the buildup fluids in soft body tissues which lead to swelling in the organs, particularly limbs. Lymphedema can lead to psychological, physical, and social problems in patients. Symptoms
Symptoms of lymphedema include loss of hair, troubled sleep, a burning sensation in legs, itching in toes and legs, a feeling of tightness when clothes, bracelets, shoes, etc. are worn, skin thickening without any changes in the skin, trouble moving arms or legs, heaviness in arms or legs, and swelling in arms or legs, which may include toes and fingers.
Diagnosis
Diagnosis may be based on past cancer history of the patient. Test such as Doppler ultrasound, CT scan, MRI scan, and radionuclide imaging of lymphatic system (lymphoscintigraphy) may be carried out.
Treatment
At present, there is no cure for lymphedema. The treatment is symptomatic and major focus is on controlling the pain and swelling. The treatment regimen may include massages, exercises, pneumatic compression, compression garments, and bandaging of the affected area.
Lymphedema Emerging Drugs Chapters
This segment of the Lymphedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, and phase I/II. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lymphedema Emerging Drugs
Lymfactin: Herantis Pharma
Lymfactin is a product which is being developed by Herantis Pharma. It is derived from the Vascular Endothelial Growth Factor C (VEGF-C), a natural human protein, which is crucial for the growth of new lymphatic vessels. Lymphfactin is a gene therapy product which works by the delivery of the human gene coding for VEGF-C, which in turn initiates the new lymphatic vessel formation. It is administered locally at the required site. It is currently available for licensing.
LYT-100:PureTechHealth
PureTech Health acquired LYT-100 in July 2019 from Auspex Pharmaceuticals. The drug candidate is in the phase I/II of drug development. The company believes that LYT-100 holds the potential to be evaluated for various inflammatory and fibrotic conditions besides being developed for lymphedema.
Further product details are provided in the report……..
Lymphedema: Therapeutic Assessment
This segment of the report provides insights about the different Lymphedema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lymphedema
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Lymphedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lymphedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphedema drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lymphedema R&D. The therapies under development are focused on novel approaches to treat/improve Lymphedema.
- Lymphedema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lymphedema drugs?
- How many Lymphedema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lymphedema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lymphedema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lymphedema and their status?
- What are the key designations that have been granted to the emerging drugs?
- PureTech Health
- Herantis Pharma
- LYT-100
- Lymfactin
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Lymphedema: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Lymphedema – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Lymphedema companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Lymphedema Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Lymfactin: Herantis Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- LYT-100: PureTech Health
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Lymphedema Key Companies
- Lymphedema Key Products
- Lymphedema- Unmet Needs
- Lymphedema- Market Drivers and Barriers
- Lymphedema- Future Perspectives and Conclusion
- Lymphedema Analyst Views
- Lymphedema Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.